Recently, studies also demonstrate that tumor mutation burden (TMB) induced antigen exposure, which is a promising biomarker to select NSCLC patients for immunotherapy, specifically in the gene mutation of MET, RET, HER2, and KRAS (16). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.